WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Biopreservation Best Practices for regenerative medicine GMP manufacturing & focus on optimized biopreservation media
I'm For Real
Enter your details once to access all our information and resources
Alltech is a family-owned company, which allows us to adapt quickly to emerging customer needs and to stay focused on advanced innovation.
whitePaper | February 11, 2022
The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.
whitePaper | November 17, 2022
Gene therapy is the modification of specific genes in targeted cells in order to address genetic mutations that cause some of the most debilitating human conditions.
whitePaper | April 7, 2020
The Internet of Things (IoT) could not be timelier for biotech/pharma. With fierce cost pressures, the push for value-based outcomes, and the need for flexible manufacturing solutions, the IoT is the much-needed shot in the arm to bring about transformational change. Sensors, actuators, and devices (“things”) embedded in production equipment and networked through computer systems can generate an enormous amount of data. The data can be mined for insights and opportunities to drive production efficiency, automate monitoring and controlling functions, and enable flexible manufacturing systems.
whitePaper | February 2, 2022
While many sectors were dealt a severe blow by the COVID-19pandemic, biotech and medtech saw continued growth andare thus attracting top candidates even for non-scientific roles.
whitePaper | November 11, 2022
Biocontamination refers to biological contamination of products by bacteria and/or fungi, as well as the toxic by-products of these microorganisms, such as endotoxin and mycotoxins from Gram-negative bacteria and fungi, respectively.
whitePaper | September 29, 2022
The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE